Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

1343550

USP

Iodixanol Related Compound D

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

Iopentol, 5-[Acetyl(2-hydroxy-3-methylpropyl)amino]-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C20H28I3N3O9
Número de CAS:
89797-00-2
Peso molecular:
835.16
Código UNSPSC:
41116107
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

iodixanol

fabricante / nombre comercial

USP

aplicaciones

pharmaceutical (small molecule)

formato

neat

InChI

1S/C20H28I3N3O9/c1-9(29)26(5-12(32)8-35-2)18-16(22)13(19(33)24-3-10(30)6-27)15(21)14(17(18)23)20(34)25-4-11(31)7-28/h10-12,27-28,30-32H,3-8H2,1-2H3,(H,24,33)(H,25,34)

Clave InChI

IUNJANQVIJDFTQ-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Iodixanol Related Compound D USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Iodixanol Injection
  • Iodixanol

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0001294

Iodixanol, European Pharmacopoeia (EP) Reference Standard

Y0001292

Iodixanol impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001291

Iodixanol impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001293

Iodixanol impurity H, European Pharmacopoeia (EP) Reference Standard

1343517

Iodixanol, United States Pharmacopeia (USP) Reference Standard

1343540

Iodixanol Related Compound C, United States Pharmacopeia (USP) Reference Standard

1343561

Iodixanol Related Compound E, United States Pharmacopeia (USP) Reference Standard

PHR3015

Iodixanol, pharmaceutical secondary standard, certified reference material

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 1

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Nikolaos L Kelekis et al.
Clinical imaging, 28(2), 124-127 (2004-03-31)
Confluent hepatic fibrosis (CHF) is usually a feature of advanced cirrhosis, while occurrence in early stage compensated cirrhosis is uncommon. We report the imaging findings of masslike CHF in a patient with previously unsuspected compensated alcoholic cirrhosis. The combination of
Markus Selzner et al.
Annals of surgery, 240(6), 1027-1034 (2004-12-01)
To compare the diagnostic value of contrast-enhanced CT (ceCT) and 2-[18-F]-fluoro-2-deoxyglucose-PET/CT in patients with metastatic colorectal cancer to the liver. Despite preoperative evaluation with ceCT, the tumor load in patients with metastatic colorectal cancer to the liver is often underestimated.
Amina Abdelmoumene et al.
European radiology, 15(9), 1881-1887 (2005-05-04)
This study compared different acquisition protocols performance to detect small liver metastases (<2 cm). Thirty consecutive patients with histologically proven hepatic metastases were explored by MDCT at the liver equilibrium phase by four successive acquisitions. We compared the following protocols
S G Spitzer et al.
Acta radiologica (Stockholm, Sweden : 1987), 43(6), 617-622 (2002-12-18)
To investigate the influence of two non-ionic radiographic contrast media with different osmolality on thrombocytic function and the plasmatic coagulation system. The study was carried out as a randomised, prospective, comparative study with two contrast media in a heart catheter
Severe Stevens-Johnson syndrome induced by contrast medium iopentol (Imagopaque).
E Laffitte et al.
The British journal of dermatology, 150(2), 376-378 (2004-03-05)
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico